Page last updated: 2024-10-14
rasfonin
Description
rasfonin: an apoptosis inhibitor; isolated from Talaromyces; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11259090 |
| MeSH ID | M0374519 |
Synonyms (10)
| Synonym |
|---|
| rasfonin |
| (a?-rasfonin |
| (2e,4e,6s)-8-hydroxy-6-(hydroxymethyl)-4-methyl-2,4-octadienoic acid, (2r,3r)-3,6-dihydro-6-oxo-2-[(1s,3r,5e)-1,3,5-trimethyl-5-hepten-1-yl]-2h-pyran-3-yl ester |
| 303156-68-5 |
| (-)-rasfonin |
| [(2r,3r)-2-[(e,2s,4r)-4,6-dimethyloct-6-en-2-yl]-6-oxo-2,3-dihydropyran-3-yl] (2e,4e,6s)-8-hydroxy-6-(hydroxymethyl)-4-methylocta-2,4-dienoate |
| CS-0082478 |
| HY-121532 |
| DTXSID301043830 |
| AKOS040756192 |
Research Excerpts
Overview
Rasfonin is a novel 2-pyrone derivative reported to induce apoptosis in ras-dependent cells. It is a fungal secondary metabolite with demonstrated antitumor effects.
| Excerpt | Reference |
|---|---|
| "Rasfonin is a novel 2-pyrone derivative reported to induce apoptosis in ras-dependent cells. " | ( Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice. Che, Y; Cheng, J; Li, L; Li, Y; Liu, F; Xiao, Z; Zhang, Y; Zheng, P; Zhou, W, 2014) |
| "Rasfonin is a fungal secondary metabolite with demonstrated antitumor effects. " | ( Akt inhibition attenuates rasfonin-induced autophagy and apoptosis through the glycolytic pathway in renal cancer cells. Che, Y; Jiang, X; Li, Y; Lu, Q; Sun, H; Wang, W; Xi, Z; Yan, S; Yang, X, 2015) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||